CLINICAL TRIALS PROFILE FOR ISTODAX
✉ Email this page to a colleague
All Clinical Trials for ISTODAX
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00053963 ↗ | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | Completed | National Cancer Institute (NCI) | Phase 1 | 2002-09-01 | This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die |
| NCT00062075 ↗ | Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | National Cancer Institute (NCI) | Phase 2 | 2003-05-01 | This phase II trial is studying how well romidepsin works in treating patients with relapsed or refractory acute myeloid leukemia. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die. |
| NCT00079443 ↗ | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma | Terminated | National Cancer Institute (NCI) | Phase 2 | 2004-01-01 | This phase I/II trial is studying the best dose of FR901228 when given together with rituximab and fludarabine and to see how well FR901228 works alone in treating patients with relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as FR901228 and fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Rituximab may increase the effectiveness of chemotherapy drugs by making cancer cells more sensitive to the drugs. |
| NCT00084461 ↗ | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | Terminated | National Cancer Institute (NCI) | Phase 2 | 2004-03-01 | Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die. |
| NCT00084682 ↗ | Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | National Cancer Institute (NCI) | Phase 2 | 2005-06-01 | This phase II trial is studying how well FR901228 works in treating patients with unresectable recurrent or metastatic squamous cell carcinoma (cancer) of the head and neck. Drugs used in chemotherapy such as FR901228 work in different ways to stop tumor cells from dividing so they stop growing or die. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ISTODAX
Condition Name
| Condition Name for ISTODAX | |
| Intervention | Trials |
| Lymphoma | 5 |
| Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | 5 |
| Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | 4 |
| Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | 4 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for ISTODAX
Trials by Country
Clinical Trial Progress for ISTODAX
Clinical Trial Phase
Clinical Trial Sponsors for ISTODAX
Sponsor Name
